Current Psychiatry Reports

, 15:426

Use of Antipsychotic Medications in Pediatric Populations: What do the Data Say?

Authors

    • Group Health Research Institute
    • Department of Health Services ResearchUniversity of Washington
  • Christine Stewart
    • Group Health Research Institute
  • Enid M. Hunkeler
    • Kaiser Permanente Division of Research, Northern California
  • Jeanne M. Madden
    • Harvard Pilgrim Health Care Research Institute
    • Department of Population MedicineHarvard Medical School
  • Janet R. Cummings
    • Department of Health Policy and Management, Rollins School of Public HealthEmory University
  • Ashli A. Owen-Smith
    • Kaiser Permanente Center for Health Research Southeast
  • Rebecca C. Rossom
    • Health Partners Institute for Education and Research
    • Department of PsychiatryUniversity of Minnesota
  • Christine Y. Lu
    • Harvard Pilgrim Health Care Research Institute
    • Department of Population MedicineHarvard Medical School
  • Frances L. Lynch
    • Kaiser Permanente Center for Health Research, Northwest
  • Beth E. Waitzfelder
    • Kaiser Permanente Center for Health Research, Hawaii
  • Karen A. Coleman
    • Kaiser Permanente Center for Health Research, Southern California
  • Brian K. Ahmedani
    • Henry Ford Health System
  • Arne L. Beck
    • Kaiser Permanente Institute for Health Research, Colorado
  • John E. Zeber
    • Center for Applied Health Research, Scott and White Healthcare and Central Texas VA
  • Gregory E. Simon
    • Group Health Research Institute
    • Department of PsychiatryUniversity of Washington
Schizophrenia and Other Psychotic Disorders (SJ Siegel, Section Editor)

DOI: 10.1007/s11920-013-0426-8

Cite this article as:
Penfold, R.B., Stewart, C., Hunkeler, E.M. et al. Curr Psychiatry Rep (2013) 15: 426. doi:10.1007/s11920-013-0426-8
Part of the following topical collections:
  1. Topical Collection on Schizophrenia and Other Psychotic Disorders

Abstract

Recent reports of antipsychotic medication use in pediatric populations describe large increases in rates of use. Much interest in the increasing use has focused on potentially inappropriate prescribing for non-Food and Drug Administration-approved uses and use amongst youth with no mental health diagnosis. Different studies of antipsychotic use have used different time periods, geographic and insurance populations of youth, and aggregations of diagnoses. We review recent estimates of use and comment on the similarities and dissimilarities in rates of use. We also report new data obtained on 11 health maintenance organizations that are members of the Mental Health Research Network in order to update and extend the knowledge base on use by diagnostic indication. Results indicate that most use in pediatric populations is for disruptive behaviors and not psychotic disorders. Differences in estimates are likely a function of differences in methodology; however, there is remarkable consistency in estimates of use by diagnosis.

Keywords

AntipsychoticsChildrenAdolescentsMedicaidMental Health Research NetworkOff-labelMarketScanIMS HealthNAMCSNDTINCS-A

Copyright information

© Springer Science+Business Media New York 2013